Literature DB >> 18799374

Distinct TPEF/HPP1 gene methylation patterns in gastric cancer indicate a field effect in gastric carcinogenesis.

A Ivanauskas1, J Hoffmann, L V Jonaitis, R Markelis, E Juozaityte, L Kupcinskas, C Lofton-Day, C Röcken, P Malfertheiner.   

Abstract

BACKGROUND: Aberrant methylation of the transmembrane protein containing epidermal growth factor and folistatin domains/hyperplastic polyposis 1 gene was recently reported in hyperplastic colon polyps, colorectal adenomas and carcinomas. However, there are only limited data on significance of transmembrane protein containing epidermal growth factor and folistatin domains/hyperplastic polyposis 1 gene methylation in gastric adenocarcinomas. AIM: The aim of this study was to determine the prevalence of transmembrane protein containing epidermal growth factor and folistatin domains/hyperplastic polyposis 1 promoter methylation in gastric adenocarcinomas. PATIENTS: Study population consists of 48 patients with gastric cancer and 11 dyspeptic patients.
METHODS: Using the Methylight assay, transmembrane protein containing epidermal growth factor and folistatin domains/hyperplastic polyposis 1 gene methylation was assessed in fresh frozen cancer tissue and matched tumoural-free area of patients with gastric cancer and in the gastric mucosa of dyspeptic patients.
RESULTS: Transmembrane protein containing epidermal growth factor and folistatin domains/hyperplastic polyposis 1 promoter gene methylation was observed in 35 of 48 (73%) gastric adenocarcinomas, and in 27 of 48 (56%) matched tumoural-free area cases (p=0.087). In contrast, the occurrence of transmembrane protein containing epidermal growth factor and folistatin domains/hyperplastic polyposis 1 methylation was much lower in gastric mucosa of dyspeptics (1 of 11; 9%) and the difference was significant in comparison with both tumoural tissue (p=0.0001) and tumoural-free area (p=0.0047) of cancer patients. Transmembrane protein containing epidermal growth factor and folistatin domains/hyperplastic polyposis 1 gene expression was significantly reduced in adenocarcinomas in comparison with matched tumoural-free area (p=0.022).
CONCLUSION: Our data suggest that methylation of transmembrane protein containing epidermal growth factor and folistatin domains/hyperplastic polyposis 1 is present in the majority of gastric adenocarcinomas and in the surrounding tumoural-free area, indicating that this epigenetic change may point to a field effect in the gastric mucosa.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18799374     DOI: 10.1016/j.dld.2008.05.004

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  5 in total

1.  Methylation of TMEFF2 gene in tissue and serum DNA from patients with non-small cell lung cancer.

Authors:  Su Man Lee; Jae Yong Park; Dong Sun Kim
Journal:  Mol Cells       Date:  2012-07-18       Impact factor: 5.034

2.  The tumor suppressor activity of the transmembrane protein with epidermal growth factor and two follistatin motifs 2 (TMEFF2) correlates with its ability to modulate sarcosine levels.

Authors:  Xiaofei Chen; Ryan Overcash; Thomas Green; Donald Hoffman; Adam S Asch; Maria J Ruiz-Echevarría
Journal:  J Biol Chem       Date:  2011-03-10       Impact factor: 5.157

3.  The interplay between histone deacetylases and c-Myc in the transcriptional suppression of HPP1 in colon cancer.

Authors:  Jian Wang; Abul Elahi; Abidemi Ajidahun; Whalen Clark; Jonathan Hernandez; Alex Achille; Ji-hui Hao; Edward Seto; David Shibata
Journal:  Cancer Biol Ther       Date:  2014-06-11       Impact factor: 4.742

4.  TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomas.

Authors:  Sidi Xie; Yunxiao Zhang; Tao Peng; Jinglin Guo; Yongfu Cao; Jing Guo; Xiaofeng Shi; Yaqin Li; Yawei Liu; Songtao Qi; Hai Wang
Journal:  Cancer Cell Int       Date:  2021-03-04       Impact factor: 5.722

5.  Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer.

Authors:  Alexander B Philipp; Dorothea Nagel; Petra Stieber; Rolf Lamerz; Isabel Thalhammer; Andreas Herbst; Frank T Kolligs
Journal:  BMC Cancer       Date:  2014-04-08       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.